2,146
Views
1
CrossRef citations to date
0
Altmetric
Original Articles: Clinical Oncology

Impact of body mass index on outcome and treatment-related toxicity in young adults with acute lymphoblastic leukemia

ORCID Icon, , , , , , , , , , & show all
Pages 1723-1731 | Received 04 Aug 2023, Accepted 08 Sep 2023, Published online: 19 Sep 2023
 

Abstract

Background

Data on outcome for patients in different body mass index (BMI) categories in young adults with acute lymphoblastic leukemia (ALL) are scarce. We explored survival and toxicities in different BMI categories in young adults with ALL.

Material and methods

Patients aged 18–45 years, diagnosed with ALL between July 2008 and June 2022 in the Nordic countries, Estonia, or Lithuania, and treated according to the NOPHO ALL2008 protocol, were retrospectively enrolled and classified into different BMI categories. Endpoints were overall survival (OS), event-free survival (EFS) and cumulative incidence of relapse as well as incidence rate ratio (IRR) of severe predefined toxic events, and treatment delays.

Results

The group comprised 416 patients, of whom 234 (56%) were stratified to non-high-risk (non-HR) treatment. In the non-HR group, patients with severe obesity, BMI ≥35 kg/m2 had worse EFS due to relapses but there was no effect on toxicity or treatment delays compared with the healthy-weight patients. There was no association between BMI category and OS, overall toxicity, or treatment delays in the patients with high-risk treatment.

Conclusion

Severe obesity is associated with worse EFS in young adults treated according to the non-HR arms of the NOPHO ALL2008 protocol. Poorer outcome is explained with a higher risk of relapse, possibly due to under treatment, and not caused by excess therapy-related mortality.

Disclosure statement

The authors report no conflicts of interest.

Data availability statement

The data that support the findings of this study are available from registry authorities, researchers are not allowed to forward confidential non-anonymous health data to any third parties. Group level data is available from the corresponding author, [CE], upon reasonable request.

Additional information

Funding

This work was supported by the Swedish Childhood Cancer Fund (Barncancerfonden) under several Grants [numbers, PR2019-0075, and TJ2018-0093].